2022
No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination
Lu-Culligan A, Tabachnikova A, Pérez-Then E, Tokuyama M, Lee HJ, Lucas C, Monteiro V, Miric M, Brache V, Cochon L, Muenker MC, Mohanty S, Huang J, Kang I, Dela Cruz C, Farhadian S, Campbell M, Yildirim I, Shaw AC, Ma S, Vermund SH, Ko AI, Omer SB, Iwasaki A. No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination. PLOS Biology 2022, 20: e3001506. PMID: 35609110, PMCID: PMC9129011, DOI: 10.1371/journal.pbio.3001506.Peer-Reviewed Original ResearchConceptsCOVID-19 mRNA vaccinationMRNA vaccinationEarly pregnancyFetal sizeCoronavirus disease 2019 (COVID-19) mRNA vaccinationSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Maternal antibody statusAdverse neonatal outcomesSyndrome coronavirus 2Birth defectsPolyinosinic-polycytidylic acidCrown-rump lengthGross birth defectsUnvaccinated adultsMaternal illnessNeonatal outcomesVaccinated adultsAntibody statusTLR3 agonistEarly immunizationMurine pregnancyAntibody inductionCoronavirus 2Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses
Wisnewski AV, Liu J, Lucas C, Klein J, Iwasaki A, Cantley L, Fazen L, Luna J, Slade M, Redlich CA. Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses. PLOS ONE 2022, 17: e0262657. PMID: 35041700, PMCID: PMC8765639, DOI: 10.1371/journal.pone.0262657.Peer-Reviewed Original ResearchConceptsPlaque reduction neutralization testCOVID-19 patientsVaccine responsesRecovered COVID-19 patientsSARS-CoV-2 immunityBooster vaccine dosesMRNA vaccine responsePost-vaccine seraCompetitive ELISAEnzyme 2 (ACE2) receptorReduction neutralization testType of vaccineSARS-CoV-2 spike protein receptorSpike protein receptorVaccine seraVaccine recipientsPost vaccinationVaccinated individualsVaccine dosesViral culturePrior historyViral neutralizationNeutralization testBooster shotsPost vaccine
2021
Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
Lucas C, Vogels CBF, Yildirim I, Rothman JE, Lu P, Monteiro V, Gehlhausen JR, Campbell M, Silva J, Tabachnikova A, Peña-Hernandez MA, Muenker MC, Breban MI, Fauver JR, Mohanty S, Huang J, Shaw A, Ko A, Omer S, Grubaugh N, Iwasaki A. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature 2021, 600: 523-529. PMID: 34634791, PMCID: PMC9348899, DOI: 10.1038/s41586-021-04085-y.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 variantsMRNA vaccine-induced immunityT-cell activation markersSARS-CoV-2 antibodiesSecond vaccine doseVaccine-induced immunityCell activation markersT cell responsesHigh antibody titresSARS-CoV-2Vaccine boosterVaccine doseActivation markersVaccine dosesHumoral immunityAntibody titresMRNA vaccinesVitro stimulationNeutralization capacityNeutralization responseCell responsesE484KNucleocapsid peptideAntibody-binding sitesGreater reductionAssociations of SARS-CoV-2 serum IgG with occupation and demographics of military personnel
Zell J, Wisnewski AV, Liu J, Klein J, Lucas C, Slade M, Iwasaki A, Redlich CA. Associations of SARS-CoV-2 serum IgG with occupation and demographics of military personnel. PLOS ONE 2021, 16: e0251114. PMID: 34460832, PMCID: PMC8405017, DOI: 10.1371/journal.pone.0251114.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Live SARS-CoV-2Moderate SARS-CoV-2SARS-CoV-2 seroprevalenceWork-related risk factorsTransportation-related occupationsSerum IgG levelsAntigen-specific IgGIgG seropositivity rateBiomarkers of infectionSARS-CoV-2 spikeCOVID-19 exposureUS National Guard soldiersMilitary personnelIgG levelsSeropositivity rateHumoral responseSerum IgGViral exposureBlack raceRisk factorsOdds ratioStudy populationNational Guard soldiersDemographic dataKynurenic acid may underlie sex-specific immune responses to COVID-19
Cai Y, Kim DJ, Takahashi T, Broadhurst DI, Yan H, Ma S, Rattray NJW, Casanovas-Massana A, Israelow B, Klein J, Lucas C, Mao T, Moore AJ, Muenker MC, Oh JE, Silva J, Wong P, team Y, Ko AI, Khan SA, Iwasaki A, Johnson CH. Kynurenic acid may underlie sex-specific immune responses to COVID-19. Science Signaling 2021, 14: eabf8483. PMID: 34230210, PMCID: PMC8432948, DOI: 10.1126/scisignal.abf8483.Peer-Reviewed Original ResearchConceptsKynurenic acidImmune responseClinical outcomesSex-specific immune responsesT cell responsesPoor clinical outcomeCOVID-19 patientsCoronavirus disease 2019COVID-19Sex-related differencesMale patientsCytokine abundanceInflammatory cytokinesKynurenine ratioSerum metabolomeDisease 2019Sex-specific linkKynurenine aminotransferaseCell responsesOld malePatientsMalesOutcomesResponseMetabolites
2018
Critical role of CD4+ T cells and IFNγ signaling in antibody-mediated resistance to Zika virus infection
Lucas CGO, Kitoko JZ, Ferreira FM, Suzart VG, Papa MP, Coelho SVA, Cavazzoni CB, Paula-Neto HA, Olsen PC, Iwasaki A, Pereira RM, Pimentel-Coelho PM, Vale AM, de Arruda LB, Bozza MT. Critical role of CD4+ T cells and IFNγ signaling in antibody-mediated resistance to Zika virus infection. Nature Communications 2018, 9: 3136. PMID: 30087337, PMCID: PMC6081430, DOI: 10.1038/s41467-018-05519-4.Peer-Reviewed Original ResearchConceptsT cellsZika virusMurine adoptive transfer modelParticipation of CD4Adoptive transfer modelT cell responsesImportance of CD4Protective adaptive immunityRapid disease onsetZika virus infectionFuture vaccine designAntibody-mediated resistanceCytotoxic CD8Viral loadZIKV infectionAntibody responsePrimary infectionRecipient miceDisease onsetVirus infectionProtective effectAdaptive immunityIFNγ signalingCD4B lymphocytes
2016
Dendritic cells primed with a chimeric plasmid containing HIV‐1‐gag associated with lysosomal‐associated protein‐1 (LAMP/gag) is a potential therapeutic vaccine against HIV
Lucas C, Matassoli F, Peçanha L, Santillo B, da Silva Oliveira L, Oshiro T, Marques E, Oxenius A, de Arruda L. Dendritic cells primed with a chimeric plasmid containing HIV‐1‐gag associated with lysosomal‐associated protein‐1 (LAMP/gag) is a potential therapeutic vaccine against HIV. The FASEB Journal 2016, 30: 2970-2984. PMID: 27199296, DOI: 10.1096/fj.201500059.Peer-Reviewed Original ResearchConceptsT cell responsesPotential therapeutic vaccineDendritic cellsTherapeutic vaccinesT cellsImmune responseHIV-specific cellular immune responsesGreater T cell responsesPotential of DCUpregulation of CD38Human dendritic cellsCellular immune responsesProtein 1Immunization of miceMouse dendritic cellsTNF-α productionHIV infectionAntibody levelsHLA-DRVaccine efficacyDNA vaccineT lymphocytesGranzyme BImmune functionVaccine vehicle
2015
Genomic Analysis, Phenotype, and Virulence of the Historical Brazilian Smallpox Vaccine Strain IOC: Implications for the Origins and Evolutionary Relationships of Vaccinia Virus
Medaglia M, Moussatché N, Nitsche A, Dabrowski P, Li Y, Damon I, Lucas C, Arruda L, Damaso C. Genomic Analysis, Phenotype, and Virulence of the Historical Brazilian Smallpox Vaccine Strain IOC: Implications for the Origins and Evolutionary Relationships of Vaccinia Virus. Journal Of Virology 2015, 89: 11909-11925. PMID: 26378174, PMCID: PMC4645304, DOI: 10.1128/jvi.01833-15.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAnimalsBase SequenceBayes TheoremBiological EvolutionBrazilCell LineComet AssayEnzyme-Linked Immunosorbent AssayFemaleFluorescent Antibody TechniqueHumansImmunoglobulin GMiceMice, Inbred BALB CModels, GeneticMolecular Sequence DataPhylogenySequence Analysis, DNASmallpoxSpecies SpecificityVaccinia virusViral VaccinesVirulenceVirulence FactorsConceptsFirst-generation vaccinesSmallpox vaccineSecond-generation smallpox vaccineVaccine strainNew-generation smallpox vaccinesVaccinia virusProtective immune responseIntensive vaccination programsImmunological featuresInfected miceHealth care standardsImmune protectionVaccination programLethal infectionImmune responseVACV strainVaccineCare standardsSmallpox eradication programmeLow virulenceAdverse effectsVACVLow pathogenicitySmallpox eradicationVaccine producers